key: cord-1050990-kyb999yx authors: V Kleandrova, Valeria; Speck-Planche, Alejandro title: The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design date: 2020-11-23 journal: Future Med Chem DOI: 10.4155/fmc-2020-0134 sha: c371deab9b72d9079419e984390f5bf88c499899 doc_id: 1050990 cord_uid: kyb999yx nan ments [6] . These therapies focus on vaccines (for example, mRNA-1273 and Ad5-nCoV), antibodies (bevacizumab, leronlimab and others), convalescent plasma or different US FDA-approved (or experimental) drugs for medical conditions other than COVID-19; the latter group includes (but is not limited to) inhibitors of viral proteins such as protease (darunavir, GC-373, etc.) and RdRp (favipiravir and nucleoside analogs [remdesivir and galidesivir]), as well as blockers of ACE2 glycosylation (chloroquine) and endosomal acidification (hydroxychloroquine), just to cite a few examples. Although these treatments may prove effective against SARS-CoV-2/COVID-19, their use as pan-antivirals is limited because they exhibit highly specific mechanisms of action. For instance, favipiravir and remdesivir are two pan-antiviral drugs that act as selective RdRp inhibitors across different viruses. Nevertheless, RdRp-exonuclease interactions imbue coronaviruses with different degrees of resistance to RdRp inhibitors [7] , thus limiting the potential applications of these antiviral agents. To the best of our knowledge, the second option -which focuses on searching for pan-antivirals acting as multitarget inhibitors -has not been explored yet. We would like to stress that multitarget drug discovery is a more complete paradigm than its one-drug-to-one target counterpart because finding multitarget inhibitors will also reveal information about target preferences and selectivity, thus providing insights for the design of selective inhibitors. In the race to find potential treatments against SARS-CoV-2/COVID-19 and other viruses, in silico models could serve as tools to identify FDA-approved drugs that can behave as pan-antivirals. Popular techniques relying on structure-based approaches (e.g., molecular docking) will always be useful but are computationally demanding if applied to the search for pan-antivirals via multitarget inhibition against diverse viral proteins. Therefore we will focus on 2D ligand-based approaches, which can be performed faster and without the diminution of accuracy. We would like to highlight three popular/important approaches that can be used to repurpose FDA-approved drugs as pan-antiviral agents. Each of them either directly or indirectly benefits from the fact that some proteins remain conserved across different viral species. Thus even if there is little information about an emerging pathogen, inhibiting different proteins of already known viruses (or the viruses themselves) could provide a starting point for inhibiting the new virus. The first approach focuses on models combining perturbation theory and machine learning (PTML) [8, 9] which, through the application of Box-Jenkins operators, can integrate in vitro screening data containing multiple viral proteins from different viruses. This enables the screening of FDA-approved drugs, and those predicted as versatile inhibitors of the viral proteins can be experimentally validated as potential treatments against SARS-CoV-2 and other viral pathogens. In the second approach, PTML models are applied to virtually screen drugs against different viruses in inhibition/replication assays. Again, the drugs predicted as pan-antivirals will be prioritized in biological testing against SARS-CoV-2. We would like to emphasize that, in antiviral research, PTML models have found successful applications in modeling anti-HIV activity through multitarget inhibition [10] , linking in vitro activity with epidemiological outcomes [11] and virtually screening antiretroviral compounds [12] . Therefore PTML models could be easily adapted and built for the two aforementioned cases. The third approach involves the development of alignment-free multitarget (AFMT) models [13] . These computational tools are constructed by calculating molecular descriptors from both the 2D structures of the ligands/inhibitors and the proteins' amino acid sequences. The advantage of the AFMT models over their PTML counterparts is that the former can predict the inhibitory potency of large libraries of (either virtual or already synthesized) chemicals against proteins other than those used to develop the AFMT models [13, 14] . AFMT models can therefore screen FDA-approved drugs against SARS-CoV-2 proteins (including the spike protein), whose sequences can be retrieved from public sources such as UniProt [15] or Protein Data Bank [16] ; the drugs predicted as multitarget inhibitors of the SARS-CoV-2 proteins can then be fast-tracked for experimental confirmation. Considering the accumulated experience, the multifactorial nature of viral infections and the limitations of current antiviral therapies, new molecular entities (NMEs) could be computationally designed as pan-antivirals. We are referring to a chemical able to inhibit multiple viruses that are dissimilar in terms of their genomes, replication, transmission, mutability and infection mechanisms. Such a pan-antiviral agent will offer a better chance of eliminating SARS-CoV-2 and other viral pathogens. To reduce both the response time against a viral pandemic and financial resources, the chosen computational approach must integrate both in vitro and in vivo assays while focusing on designing a small library of 5-20 chemicals that virtually exhibit potent pan-antiviral activity, low toxicity and adequate pharmacokinetic properties. To date, the most suitable approach capable of designing an NME is multiscale de novo drug design [17] , which involves four steps. First, a multitasking model for quantitative structure-biological effect relationships (mtk-QSBER) is built [18] . Then the most common molecular fragments present in the dataset used to create the model are extracted and their quantitative contributions to the pan-antiviral activity and the safety profiles are calculated; fragments with positive contributions will be used as building blocks to design NMEs. Third, the molecular descriptors present in the mtk-QSBER model are interpreted, providing information regarding the physicochemical properties and structural features that a molecule should possess to simultaneously display panantiviral activity, reduced toxicity and desirable pharmacokinetic profiles. Last, NMEs are generated by assembling fragments with positive contributions according to the interpretations of the molecular descriptors. In the context of antiviral research, multiscale de novo drug design has been successfully applied to the virtual generation of anti-hepatitis C agents [19] and anti-HIV compounds [20] . This approach represents the fastest and most economical solution to discover potent and safe pan-antivirals while preventing promiscuous (off-target) interactions potentially associated with side effects. Viral infections represent a constant threat to humanity. The latest viral outbreaks have derived from RNA-based viruses, but it must not be taken for granted that DNA-based viruses are unable to cause pandemics. Developing pan-antiviral agents is perhaps the most efficient way to tackle all the emerging and re-emerging viral pathogens. The search for such therapeutic agents should be performed with the aim of finding chemicals that will disrupt dissimilar mechanisms of action, stopping the biomolecular machinery of viral infection and/or replication across multiple viral species. Computational approaches are and will be essential in accelerating the search for pan-antiviral agents, either by repurposing drugs with multitarget inhibition patterns via the PTML and AFMT models, or by using multiscale de novo drug design to rationally generate NMEs with the desired properties. Financial & competing interests disclosure Broad-spectrum antiviral agents An interactive web-based dashboard to track COVID-19 in real time Innovation in the pharmaceutical industry: new estimates of R&D costs Discovering drugs to treat coronavirus disease 2019 (COVID-19) DrugBank: a comprehensive resource for in silico drug discovery and exploration DrugBank: COVID-19 information Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites Modeling antibacterial activity with machine learning and fusion of chemical structure information with microorganism metabolic networks Enabling the discovery and virtual screening of potent and safe antimicrobial peptides. Simultaneous prediction of antibacterial activity and cytotoxicity A ligand-based approach for the in silico discovery of multi-target inhibitors for proteins associated with HIV infection ANN multiscale model of anti-HIV drugs activity vs AIDS prevalence in the US at county level based on information indices of molecular graphs and social networks Multioutput perturbation-theory machine learning (PTML) model of ChEMBL data for antiretroviral compounds 3D-QSAR methodologies and molecular modeling in bioinformatics for the search of novel anti-HIV therapies: rational design of entry inhibitors Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors UniProt: the universal protein knowledgebase The Protein Data Bank Recent advances in fragment-based computational drug design: tackling simultaneous targets/biological effects Multitasking models for quantitative structure-biological effect relationships: current status and future perspectives to speed up drug discovery Speeding up early drug discovery in antiviral research: a fragment-based in silico approach for the design of virtual anti-hepatitis C leads Multitasking model for computer-aided design and virtual screening of compounds with high anti-HIV activity and desirable ADMET properties The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.